Literature DB >> 2156946

Herpes simplex virus type 2 meningoencephalitis resistant to acyclovir in a patient with AIDS.

A Gateley1, R M Gander, P C Johnson, S Kit, H Otsuka, S Kohl.   

Abstract

A case is reported of relapsing fatal meningoencephalitis caused by a neurovirulent thymidine kinase-positive (TK+) type 2 herpes simplex virus (HSV) that developed thymidine kinase deficiency (TK-) during intravenous acyclovir therapy. A patient with AIDS was admitted for acyclovir treatment of a persistent perirectal herpetic ulcer. He subsequently developed meningoencephalitis. A TK+ type 2 HSV was isolated from a brain biopsy specimen. A progressive and fatal relapse occurred, and a TK- type 2 HSV was isolated from his cerebrospinal fluid. Restriction endonuclease analysis of viral DNA from perianal, brain, and cerebrospinal fluid isolates were similar, suggesting that they were the same viral strain. Animal virulence studies indicated significant cutaneous virulence in immunocompromised mice models for the TK- isolates. This case is notable because TK- HSV have, in the past, lacked neurovirulence and because acyclovir resistance developed during therapy and caused the patient's death.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2156946     DOI: 10.1093/infdis/161.4.711

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  22 in total

Review 1.  Resistance of herpesviruses to antiviral drugs.

Authors:  P A Chatis; C S Crumpacker
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

Review 2.  Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management.

Authors:  Jocelyne Piret; Guy Boivin
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

3.  Genital HSV-1 infections.

Authors:  A Wald
Journal:  Sex Transm Infect       Date:  2006-06       Impact factor: 3.519

4.  In Vitro and In Vivo Activity, Tolerability, and Mechanism of Action of BX795 as an Antiviral against Herpes Simplex Virus 2 Genital Infection.

Authors:  James Hopkins; Tejabhiram Yadavalli; Rahul Suryawanshi; Farreh Qatanani; Ipsita Volety; Ram Koganti; Aqsa Iqbal; Deepak Shukla
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

Review 5.  Antiviral therapy: current concepts and practices.

Authors:  B Bean
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

6.  Susceptibilities of several drug-resistant herpes simplex virus type 1 strains to alternative antiviral compounds.

Authors:  G Andrei; R Snoeck; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

7.  A net +1 frameshift permits synthesis of thymidine kinase from a drug-resistant herpes simplex virus mutant.

Authors:  C B Hwang; B Horsburgh; E Pelosi; S Roberts; P Digard; D M Coen
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-07       Impact factor: 11.205

Review 8.  "The end of innocence" revisited: resistance of herpesviruses to antiviral drugs.

Authors:  A K Field; K K Biron
Journal:  Clin Microbiol Rev       Date:  1994-01       Impact factor: 26.132

Review 9.  Molecular methods for diagnosis of viral encephalitis.

Authors:  Roberta L Debiasi; Kenneth L Tyler
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

Review 10.  Clinical and therapeutic issues for herpes simplex virus-2 and HIV co-infection.

Authors:  Jairam R Lingappa; Connie Celum
Journal:  Drugs       Date:  2007       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.